Another potential therapeutic molecular target in MM is fibroblast growth factor receptor−3 (FGFR3), which overexpression correlates with the translocation t(4;14) (p16;q32), present in ~20% of MM patients. Here, FGFR3 is linked to Miyoshi myopathy.